文档介绍：Articles 381 January 12, 2013 117 Lancet 2013; 381: 117–24 Published Online November 7, 2012 http://dx.// S0140-6736(12)61267-7 See Comment page 93 University of North Carolina School of Medicine, Chapel Hill, NC, USA (Prof J B Buse MD) ; Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany (Prof M Nauck MD) ; Institute for Clinical Research and Development, Mainz, Germany (Prof T Forst MD) ; Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, School of Medicine, National Yang-Ming University, Taipei, Taiwan (Prof W H-H Sheu MD) ; Eli Lilly pany, Indianapolis, IN, USA (S K Shenouda PhD, C R Heilmann PhD, B J Hoogwerf MD, M K Boardman PharmD) ; /i3, Cincinnati, OH, USA (A Gao PhD) ; Elcelyx Therapeutics, San Diego, CA, USA (M Fineman PhD) ; Amylin Pharmaceuticals, San Diego, CA, USA (L Porter MD) ; and Rudolfstiftung Hospital, Vienna, Austria (Prof G Schernthaner MD) Correspondence to: Prof Guntram Schernthaner, Rudolfstiftung Hospital, A-1030 Vienna, Austria @ Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study John B Buse, Michael Nauck, Thomas Forst, Wayne H-H Sheu, Sylvia K Shenouda, Cory R Heilmann, Byron J Hoogwerf, Aijun Gao,